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doi:10.1016/j.jtcvs.2007.04.021bjective: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors,
sed routinely in patients with coronary disease, can improve endothelial function
ut can have biphasic and dose-dependent effects on angiogenesis. In vitro evidence
uggests that the proangiogenic effects of statins are linked to activation of Akt, a
ediator of endothelial cell survival and an activator of endothelial nitric oxide
ynthase. We investigated the functional and molecular effects of atorvastatin
upplementation on microvascular function and the endogenous angiogenic re-
ponse to chronic myocardial ischemia in normocholesterolemic swine.
ethods: Yucatan miniswine were fed a normal diet with (ATOR, n 7) or without
control, n  8) atorvastatin (1.5 mg/kg/d) for 20 weeks. Chronic ischemia was
nduced by ameroid constrictor placement around the circumflex artery. Myocardial
erfusion was assessed at 3 and 7 weeks using isotope-labeled microspheres. In vitro
icrovessel relaxation responses and myocardial protein expression were evaluated.
esults: Endothelium-dependent relaxation to adenosine diphosphate and
ndothelium-independent relaxation to sodium nitroprusside were intact in both
roups. The ATOR group demonstrated impaired microvessel relaxation to vascular
ndothelial growth factor (53% 3% vs 70% 7%, ATOR vs NORM at 1010 mol/L,
 .05) and fibroblast growth factor-2 (35%  3% vs 57%  5%, ATOR vs NORM
t 1010 mol/L, P  .04). Baseline-adjusted myocardial perfusion in the ischemic
ircumflex territory was significantly reduced in the ATOR group (0.29  0.10
L/min/g vs NORM, P .009). Phosphorylation of Akt was significantly increased in
he ATOR group (235%  72%, P  .009 vs NORM), as was the myocardial
xpression of endostatin, an antiangiogenic protein (51% 9%, P .001 vs NORM).
xpression of vascular endothelial growth factor, Tie-2, fibroblast growth factor recep-
or-1, and endothelial nitric oxide synthase was similar in both groups.
onclusions: Atorvastatin supplementation is associated with impaired growth
actor–mediated microvessel relaxation and a significant reduction in collateral-
ependent perfusion. Chronic Akt activation, increased myocardial expression of
ndostatin, and impaired growth factor signaling may account for the diminished
ndogenous angiogenic response observed with atorvastatin treatment.
tatins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are
commonly used in patients with coronary artery disease with or without
hypercholesterolemia and can improve peripheral and coronary endothelialysfunction in these patients.1 Numerous clinical studies have demonstrated the
The Journal of Thoracic and Cardiovascular Surgery ● Volume 135, Number 1 117
b
p
s ug
g
a en
l 73),
w
m
t
h
c
p
a
e
s
k
f
f er
e
o
u
t
r
m
M
G
F
C
w
g
s
a
f
v
p u
m
t
C
p
t
t
(
t
a
q
c
e
1
d
i
d
d
f
a
h
w
p
m
t
p
m
C
s
a
c
s
u
I
M
A
i
t
f
e ly.
T
a
m
a
g
t
w
p
t
s
c
g
A
M
i
u
1
e
i
m
c
g
w
Cardiopulmonary Support and Physiology Boodhwani et al
1
CSPenefits of statins in preventing cardiovascular events in
atients with coronary disease and after coronary bypass
urgery.2,3 However, in vitro and murine evidence has s-
ested a biphasic and dose-dependent effect of statins on
ngiogenesis.4,5 Proangiogenic effects of statins have be
inked to phosphorylation and activation of Akt (Ser 46
hich has several downstream effects, including the pro-
otion of endothelial cell survival and activation of endo-
helial nitric oxide synthase (eNOS). On the other hand,
igh doses of statins have an inhibitory effect on endothelial
ell migration, and the antioxidant effects of statins can
otentially interfere with reactive oxygen species-mediated
ngiogenic signaling. In the setting of hypercholesterol-
mia-induced endothelial dysfunction, we have demon-
trated that high-dose atorvastatin supplementation (3 mg/
g) reduces cholesterol levels and improves endothelial
unction but fails to improve the endogenous7 or growth
actor-induced8 myocardial angiogenic response. To furth
xamine the effects of atorvastatin under normocholester-
lemic conditions, we evaluated the functional and molec-
lar effects of atorvastatin at a lower dose (1.5 mg/kg) on
he microvascular function and the endogenous angiogenic
esponse in a clinically relevant porcine model of chronic
yocardial ischemia.
aterials and Methods
eneral Experimental Sequence
ifteen Yucatan miniswine of either sex (Sinclair Research Inc,
olombia, Mo) were used for the studies. After weaning at 7
eeks of age, the animals were divided into 2 groups. The first
roup was fed a regular pig chow (NORM group; N  8), and the
econd group was fed a regular pig chow supplemented with
torvastatin at an oral dose of 1.5 mg/kg/d (ATOR group; n  7)
or the duration of the study (total 20 weeks).
All animals underwent an identical experimental protocol in-
olving 3 separate procedures on each animal. Anesthesia was
erformed as reported previously,9 and all animals received h-
ane care in compliance with the Harvard Medical Area Institu-
ional Animal Care and Use Committee and the National Research
ouncil’s Guide for the Care and Use of Laboratory Animals,
repared by the Institute of Laboratory Animals and published by
he National Institutes of Health (Publication No. 5377-3 1996).
The first procedure, performed through a small left anterolateral
horacotomy at 20 weeks of age, consisted of ameroid constrictor
1.75-mm) placement around the proximal circumflex artery and
he injection of 1.5  107 gold-labeled microspheres into the left
Abbreviations and Acronyms
eNOS  endothelial nitric oxide synthase
FGF  fibroblast growth factor
ILM  isotope-labeled microsphere
VEGF vascular endothelial growth factortrium during temporary circumflex coronary occlusion to subse- b
18 The Journal of Thoracic and Cardiovascular Surgery ● Januuently allow for identification, by shadow labeling, of the myo-
ardial territory at risk.
The second procedure, also performed through a left anterolat-
ral thoracotomy, 3 weeks after ameroid placement, consisted of
.5  107 lutetium microspheres injected into the left atrium
uring rest conditions and 1.5  107 europium microspheres
njected during rapid atrial pacing (150 beats/min) to allow for
etermination of baseline perfusion after ameroid closure. To
ocument ameroid closure, left coronary angiography was per-
ormed through an 8F sheath surgically inserted in the femoral
rtery, using a catheter with the appropriate distal angulation and
igh atomic weight contrast.
The third procedure was carried out at 27 weeks of age (4
eeks after the second procedure and 7 weeks after ameroid
lacement). A sternotomy was performed, 1.5  107 samarium
icrospheres were injected into the left atrium during rest condi-
ions, and 1.5  107 lanthanum microspheres were injected during
acing (150 beats/min). Euthanasia was then performed with 10
L/kg of a saturated KCl solution administered intravenously.
ardiac samples were harvested and snap-frozen for molecular
tudies, sectioned, weighed, and dried for myocardial microsphere
nalyses, and put in 4°C Kreb’s solution for in vitro assessment of
oronary microvascular reactivity. Ameroid constrictors were re-
ected along with a segment of circumflex artery and examined
nder low-power magnification.
n Vitro Assessment of Coronary
icrovessel Reactivity
fter cardiac harvest, epicardial coronary arterioles (80–150 m
n diameter and 1–2 mm in length) originating from branches of
he left anterior descending and circumflex arteries were dissected
rom the surrounding tissue with a 40 dissecting microscope and
xamined in isolated organ chambers, as described previous9
he responses to sodium nitroprusside (1 nM to 100 M),
n endothelium-independent cyclic guanosine monophosphate-
ediated vasodilator, adenosine 5’-diphosphate (1 nM to 10 m),
n endothelium-dependent receptor-mediated vasodilator, and
rowth factors, vascular endothelial growth factor (VEGF) (1 fM
o 1 nM) and fibroblast growth factor (FGF)-2 (1 fM to 1 nM),
hich act through bioavailable nitric oxide, were studied after
recontraction by 30% to 50% of the baseline diameter with the
hromboxane A2 analog U46619 (0.1-1 mol/L). Relaxation re-
ponses were defined as the percentage of relaxation of the pre-
ontracted diameter, and 6 to 8 vessels were examined in each
roup from the left anterior descending and circumflex territories.
ssessment of Myocardial Perfusion
yocardial perfusion was assessed during each procedure with
sotope-labeled microspheres (ILMs) (BioPAL, Worcester, Mass)
sing methods previously reported.9 Isotope-labeled microspheres,
5 m in diameter, of different isotopic mass were used at each
xperimental stage. Gold-labeled microspheres were injected dur-
ng temporary circumflex occlusion at the time of ameroid place-
ent to identify myocardial samples that originated from the
ircumflex coronary distribution (those with the lowest count of
old-labeled microspheres). Lutetium and europium-labeled ILMs
ere used during the second procedure to determine baseline
lood flow at rest and with pacing. Samarium and lanthanum-
ary 2008
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Pabeled ILMs were injected at rest and during atrial epicardial
acing at 150 beats/min during the third procedure. After eutha-
asia, 10 circumferential transmural left ventricular sections were
ollected for ILM assays in each animal, weighed, and dried. Each
ample was exposed to neutron beams, and microsphere densities
ere measured in a gamma counter. Adjusted myocardial blood
ow (at rest and with pacing), reflecting changes in lateral myo-
ardial perfusion, was determined from the 2 myocardial samples
hat showed the lowest count of red microspheres by using the
ollowing equation:
djusted blood flow crude blood flow (third surgery)
 crude blood flow at baseline (second surgery)
mmunohistochemistry
yocardial sections from the circumflex territory of NORM and
TOR animals were stained with antiplatelet endothelial cell
dhesion molecule-1 (CD-31) antibody diluted to 1:600 (BD Bio-
ciences Pharmingen, San Diego, Calif), as previously described.9
he sections were counterstained with methyl green and examined
or capillary endothelial cell density in a triplicate, blinded fashion
rom 700  550 m (0.385 mm2) cross-sectional fields randomly
elected from the center of the ischemic circumflex territory.
estern Blotting
hole-cell lysates were isolated from the homogenized myo-
ardial samples with a radioimmunoprecipitation assay buffer
Boston Bioproducts, Worcester, Mass) and centrifuged at
2,000g for 10 minutes at 4°C to separate soluble from insol-
ble fractions. Protein concentration was measured spectropho-
ometrically at a 595-nm wavelength with a DC protein assay
it (Bio-Rad, Hercules, Calif). Forty micrograms of total pro-
ein were fractionated by 4% to 20% gradient and sodium
odecylsulfate polyacrylamide gel electrophoresis (Invitrogen,
an Diego, Calif) and transferred to polyvinylidene difluoride
embranes (Millipore, Bedford, Mass). Each membrane was
ncubated with specific antibodies as follows: anti-VEGF anti-
ody diluted to 1:250 (Calbiochem, San Diego, Calif), anti-
NOS antibody diluted to 1:2500 (BD Biosciences, San Jose,
alif), anti-endostatin antibody diluted to 1:1000 (Upstate, Chi-
ago, Ill), anti-phospho-Akt (Cell Signaling, Danvers, Mass),
GF receptor-1 (Zymed, San Francisco, Calif). Then the mem-
ranes were incubated for 1 hour in diluted appropriate second-
ry antibody (Jackson Immunolab, West Grove, Pa). Immune
omplexes were visualized with the enhanced chemilumines-
ence detection system (Amersham, Piscataway, NJ). Bands
ere quantified by densitometric of radioautograph films.
ata Analysis
ata are reported as means  standard error of the mean. Mi-
rovessel responses are expressed as percent relaxation of the
reconstricted diameter and were analyzed using 2-way, repeated-
easures analysis of variance examining the relationship among
essel relaxation, log concentration of the vasoactive agent of
nterest, and the experimental group. Immunoblots are expressed
s a ratio of protein to loading band density and were analyzed
fter digitization and quantification of x-ray films with ImageJ 1.33
National Institutes of Health, Bethesda, Md). Blots and ILM data (
The Journal of Thoracicere analyzed with 2-tailed t tests. Bonferroni corrections were
pplied to multiple tests. Statistical analyses were conduced using
AS Version 9.1 (SAS Inc, Cary, NC), and figures were generated
sing GraphPad Prism (GraphPad, San Diego, Calif).
esults
oronary Microvessel Reactivity
igure 1 shows the results of microvessel relaxation stu
aseline diameter was similar between the NORM and
TOR groups (125  12 m vs 133  8 m, NORM vs
TOR, P  .59), as was the degree of preconstriction with
he thromboxane A2 analog, U46619 (41%  6% vs
4%  3%, P  .32). There were no significant differ-
nces in microvessel relaxation to any vasodilators in the
onischemic left anterior descending territory. In the
schemic circumflex territory, atorvastatin-treated ani-
als demonstrated impaired microvessel relaxation to
EGF (P  .05) and basic FGF-2 (P  .04). Relaxation
o adenosine 5’-diphosphate and sodium nitroprusside
as similar between groups.
yocardial Perfusion
hree weeks after ameroid placement, baseline myocardial
erfusion of the ischemic circumflex territory at rest was
imilar between the NORM and ATOR groups (0.49 0.07
L/min/g vs 0.58  0.04 mL/min/g; P  .23). During the
ubsequent 4 weeks, there was an increase in baseline-
djusted circumflex territory perfusion (0.11  0.08 mL/
in/g) in the NORM group, reflecting the endogenous re-
ponse to chronic myocardial ischemia. The atorvastatin-
reated animals, however, demonstrated a reduction in
aseline-adjusted circumflex territory perfusion compared
ith the NORM group (0.19  0.06 mL/min/g, P  .009;
igure 2). Similar trends were seen under pacing condi
0.20  0.06 vs 0.26  0.09, P  .001).
ndothelial Cell Density
ndothelial cell density (Figure 3) was significantly redu
n the ischemic territory of atorvastatin-treated animals
ompared with controls (111  11 vs 152  12 counts/
igh-power field; P  .02).
olecular Studies
yocardial expression of proangiogenic and antiangiogenic
ediators is depicted in Figure 4. Atorvastatin-treated 
als demonstrated a marked increase in Akt phosphoryla-
ion (3-fold, P .009) without significant changes in total
kt expression. Expression of VEGF, eNOS, Tie-2, and
GF receptor-1 was similar between groups. Expression of
ndostatin, an antiangiogenic protein, was significantly and
onsistently increased in the atorvastatin-treated animals
1.5-fold, P  .001).
and Cardiovascular Surgery ● Volume 135, Number 1 119
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CSPiscussion
n this study, we found that normocholesterolemic swine
reated with high-dose atorvastatin exhibited a significant
mpairment in the angiogenic response to chronic myocar-
ial ischemia. This conclusion was supported by decreased
erfusion of the collateral-dependent circumflex territory
nd the histologic finding of reduced endothelial cell density
n the ischemic territory of atorvastatin-treated animals. We
igure 2. Atorvastatin-treated animals demonstrated decreased
aseline-adjusted perfusion of the ischemic circumflex territory
ompared with controls, both at rest and under pacing conditions
*P  .009, **P < .001).20 The Journal of Thoracic and Cardiovascular Surgery ● Janulso found that atorvastatin-treated animals demonstrated re-
uced coronary microvessel relaxation in response to VEGF
nd FGF-2, suggesting impairments in growth factor-mediated
ignaling. Exploration of molecular pathways revealed in-
reased expression of the potent antiangiogenic protein en-
Figure 1. Microvessel response to
endothelium-dependent vasodilator
adenosine diphosphate and endothelium-
independent vasodilator sodium nitroprus-
side were similar between groups. Both
VEGF and FGF-2–mediated microvessel re-
laxation were impaired in the ischemic
territory of atorvastatin-treated animals.
*P  .05. ADP, Adenosine diphosphate;
SNP, sodium nitroprusside; VEGF, vascular
endothelial growth factor; FGF, fibroblast
growth factor.
igure 3. Endothelial cell density was determined by counting
he number of CD31 cells per high power field (0.263 mm2) in
yocardial sections from the ischemic circumflex territory.
torvastatin-treated swine demonstrated significantly reduced
ndothelial density compared with controls (P  .02).ary 2008
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Postatin and increased Akt activation in atorvastatin-treated
nimals. In summary, high-dose atorvastatin supplementation
esulted in a reduced angiogenic response to chronic myocar-
ial ischemia in normocholesterolemic swine.
There are a number of possible explanations for anti-
ngiogenic effects of statins. Weis and colleagues5 demon-
trated that endothelial cell proliferation, migration, and
ifferentiation are impaired in the presence of high-dose
erivastatin. Furthermore, endothelial cell release of VEGF
s diminished and endothelial cell apoptosis is increased
nder these conditions. Urbich and colleagues4 corroborated
hese findings using atorvastatin and established that statins
xert these effects on endothelial cells through the down-
tream activation of Akt. Park and colleagues10 also ob-
erved the antiangiogenic effects of simvastatin in response
o VEGF and FGF-2 in chick chorioallantoic membranes;
hey observed that statins interfered with VEGF signaling in
itro. Last, statin treatment has also been shown to reduce
erum levels of VEGF in hypercholesterolemic patients11
We previously demonstrated, in a swine model of
ypercholesterolemia-induced endothelial dysfunction, that
torvastatin supplementation (3 mg/kg/d) improves endo-
helial function but does not improve the endogenous7 or
rowth factor–induced8 angiogenic response to chroni
yocardial ischemia. This dose is approximately equiva-
ent, in humans, to 160 mg per day and from a clinical
erspective may represent a supratherapeutic dose. To val-
date our findings, in this study, we evaluated the effects of
clinically relevant but a high dose of oral atorvastatin (1.5
g/kg/d, ie, approximately equivalent to 80 mg/d) on myo-
ardial angiogenesis. In contrast with control animals that
emonstrated an endogenous angiogenic response to chronic
schemia, atorvastatin-treated animals exhibited reductions in
erfusion of the ischemic, collateral-dependent circumflex
erritory.
Three important findings from this study provide mech-
nistic insight into the observed impairment in angiogenic i
The Journal of Thoracicesponse. First, in ex vivo microvessel relaxation studies we
ound that both vascular smooth muscle function and
ndothelium-dependent nitric oxide release were preserved
n atorvastatin-treated animals. However, the microvessel
elaxation responses to VEGF and FGF-2 were attenuated,
uggesting an impairment in VEGF and FGF-2 signaling
independent of nitric oxide bioavailability) at the level of
he receptor or downstream mediators. Second, we found
hat phosphorylation and activation of the downstream me-
iator, Akt, was chronically increased approximately 3-fold
n the myocardium of atorvastatin-treated animals. Because
EGF exerts its downstream effects, in part, through Akt
ctivation,12 this persistent Akt activation resulting fro
tatin exposure may interfere with native VEGF signaling.
urthermore, chronic Akt activation has been demonstrated
o have detrimental effects on the myocardium in the setting
f ischemia-reperfusion.13 Last, increased expression of t
otent antiangiogenic protein endostatin has consistently
een observed by our group in the setting of atorvastatin
reatment. Endostatin, a 20-kD cleavage product of collagen
VIII, has been shown to inhibit endothelial cell prolifer-
tion, migration, and vascular tube formation, and to pro-
ote endothelial cell apoptosis.14,15 Increased endostatin in
he myocardium of atorvastatin-treated animals may con-
ribute to reduced new vessel formation in response to
hronic ischemia.
In light of the increasing evidence suggesting antiangio-
enic properties of statins, it is critical to define the rele-
ance of these findings to patients with coronary disease
ho stand to benefit from long-term statin treatment. One of
he many proposed pleiotropic effects of statins is the sta-
ilization of atherosclerotic plaque, which can reduce the
hance of plaque rupture, thereby reducing the incidence of
cute coronary thrombosis and myocardial injury.16 Plaque
upture has been clearly linked to plaque angiogenesis, that
s, through the disruption of the fragile blood vessels found
Figure 4. Myocardial expression of endostatin was
significantly increased in atorvastatin-treated ani-
mals (*P < .001). Phosphorylation of Akt was also
increased with atorvastatin treatment (**P  .009).
Expression of Akt, eNOS, VEGF, Tie-2, and FGF
receptor-1 was similar between groups. eNOS, en-
dothelial nitric oxide synthase; FGFR, fibroblast
growth factor receptor.n the vaso vasora of atherosclerotic arteries. Antiangio-
and Cardiovascular Surgery ● Volume 135, Number 1 121
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CSPenic properties of high-dose statins may, in fact, be respon-
ible for the plaque stabilization effects that have been
bserved. There is some suggestion that high-dose statins
ay also have antineoplastic effects.17 Given the critica
ole of angiogenesis in the pathophysiology of neoplastic
rocesses, it is possible that the observed antineoplastic
roperties of statins are due to their antiangiogenic effects.
Statins, particularly high-dose statins, have well-
ocumented benefits in patients with coronary disease;
herefore, any application of these preclinical data to the
linical setting would first require well-controlled, random-
zed studies in patients with well-defined end points to
valuate the long-term effects of high-dose statins on col-
ateral vessel formation. Unfortunately, these studies will be
imited, in part, by the currently available imaging modal-
ties that lack the sensitivity and resolution to clearly detect
mall changes in collateral vessel formation. If proven true
n clinical studies, however, these antiangiogenic properties
f statins would be an important consideration in weighing
he risks and benefits of long-term statin therapy in patients
ith end-stage coronary disease in whom collateral vessel
evelopment can be a lifesaving process.
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